Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;17(1):1-11.
doi: 10.1080/14760584.2018.1407650. Epub 2017 Nov 27.

Quadrivalent Inactivated Influenza Vaccine (VaxigripTetra™)

Affiliations
Review

Quadrivalent Inactivated Influenza Vaccine (VaxigripTetra™)

Viviane Gresset-Bourgeois et al. Expert Rev Vaccines. .

Abstract

VaxigripTetra™ (IIV4; Sanofi Pasteur) is a quadrivalent split-virion influenza vaccine approved in Europe in 2016 for individuals ≥ 3 years of age. IIV4 builds on the well-established record of the trivalent split-virion influenza vaccine (Vaxigrip®). Areas covered: This literature review summarizes the rationale for developing quadrivalent influenza vaccines and discusses the phase III clinical trial results supporting the immunogenicity, safety, and tolerability of IIV4. Expert commentary: IIV4 is immunogenic and well tolerated. Adding a second B strain to the trivalent split-virion influenza vaccine provides a superior immune response for the additional strain but does not reduce the immune response for the three other strains or negatively affect the safety profile. By offering broader protection against co-circulating influenza B lineages, IIV4 has the potential to further reduce influenza-related morbidity and mortality beyond that achieved with trivalent vaccines.

Keywords: Clinical trial; immunogenicity; inactivated influenza vaccine; influenza B; quadrivalent influenza vaccine; safety.

Similar articles

See all similar articles

Cited by 3 articles

MeSH terms

LinkOut - more resources

Feedback